Pacira BioSciences (PCRX) Gross Margin (2010 - 2026)

Pacira BioSciences' Gross Margin history runs 17 years deep, the most recent figure standing at 79.47% for Q1 2026.

• In Q1 2026, Gross Margin fell 22.0% year-over-year to 79.47%; the TTM figure through Mar 2026 stood at 79.34% (up 172.0% YoY), while the FY2025 annual figure was 79.39%, up 370.0% from the prior year.
• Gross Margin was 79.47% for Q1 2026 at Pacira BioSciences, roughly flat from 79.53% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 112.91% in Q4 2022 to a low of 69.43% in Q1 2023.
• Historically, Gross Margin has averaged 77.63% across 5 years, with a median of 76.95% in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Margin jumped 3741 bps in 2022, then tumbled 3922 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 112.91% in 2022, then plunged by 35 bps to 73.69% in 2023, then climbed by 7 bps to 78.7% in 2024, then grew by 1 bps to 79.53% in 2025, then retreated by 0 bps to 79.47% in 2026.
• The last three Gross Margin figures came in at 79.47% (Q1 2026), 79.53% (Q4 2025), and 80.91% (Q3 2025), per Business Quant data.